Most people shopping for probiotics make the same mistake: they look at the CFU count on the label, assume bigger is better, and buy whatever is on sale. CFU count — colony forming units — is essentially a marketing number. It tells you how many live bacteria were in the product at the time of manufacture, not how many survive to your colon, and not whether those particular bacteria do anything useful for IBS.
What matters in IBS is strain specificity. This is not a nuance — it's the central issue in probiotic efficacy research. Different species of the same genus, and different strains of the same species, produce completely different effects on gut motility, the microbiome, and intestinal inflammation. A probiotic that relieves IBS-C (constipation-predominant) may worsen IBS-D (diarrhea-predominant). A strain with strong evidence for bloating has nothing to do with one that improves stool consistency.
The good news is that there are several strains with legitimate clinical trial evidence specifically for IBS. The bad news is that most commercial probiotics don't use these strains, or don't use them in adequate doses.
Why strain specificity is not optional in IBS
IBS is a functional gut disorder characterized by abdominal pain, altered bowel habits, and bloating — but the mechanisms differ between subtypes. IBS-D (diarrhea-predominant) involves motility issues and potentially different microbiome dysbiosis patterns than IBS-C (constipation-predominant) or IBS-M (mixed). IBS-PI (post-infectious) has its own distinct pathology involving post-infectious gut inflammation.
A probiotic works by competing with pathogenic organisms, modulating gut immune function, producing short-chain fatty acids, influencing gut motility, and strengthening the intestinal barrier. Which of these effects predominates depends entirely on the specific strain. You cannot extrapolate from one strain to another even within the same genus.
Bifidobacterium longum 35624 (Alflorex/Align): the most evidence-based single strain
B. longum 35624 is the strain in Align (US) and Alflorex (UK/EU). It was developed at University College Cork specifically for IBS, and it has the most consistent single-strain RCT evidence of any probiotic for IBS.
A 2011 double-blind RCT in the American Journal of Gastroenterology found 1 billion CFU of B. longum 35624 significantly reduced abdominal pain/discomfort, bloating, and bowel habit irregularity compared to placebo after 8 weeks. The effects were seen across IBS subtypes.
The mechanism involves modulation of intestinal dendritic cells, which reduces inflammation in the gut lining and may explain why this strain helps IBS patients regardless of the predominant symptom pattern.
Dose: 1 billion CFU once daily (this is the studied dose — more is not necessarily better here)
Product: Align Probiotic (uses the strain directly). No generic equivalent provides the same strain.
Who it's best for: IBS with predominantly abdominal pain and bloating across subtypes.
Lactobacillus plantarum 299v: for bloating and gut transit
L. plantarum 299v is supported by multiple RCTs specifically for IBS. A 2001 RCT in the European Journal of Gastroenterology and Hepatology found significant reduction in flatulence and abdominal pain after 4 weeks. A 2012 Swedish study replicated these findings with significant improvements in pain intensity and frequency.
This strain works partly by adhering to the intestinal mucosa and competing with pathogenic bacteria, and partly through its effects on gut motility — it appears to normalize gut transit time, which may explain its efficacy in both IBS-C and IBS-D (by working toward a normalized middle).
Dose: 10–20 billion CFU daily
Products: Probi Digestis (the original; not widely available in the US), Good Belly Probiotic Shots (uses this strain), some health food stores carry it under the 299v designation
Who it's best for: IBS with predominant bloating, gas, and pain; reasonable evidence for both IBS-C and IBS-D.
VSL#3: the multi-strain formula with the most IBS trial data
VSL#3 is a high-potency multi-strain probiotic combination containing 8 strains: four Lactobacillus strains, three Bifidobacterium strains, and Streptococcus thermophilus. It delivers 112.5 billion CFU per sachet (or 450 billion in the medical food version).
This is not a typical consumer probiotic — it's used as a medical food in clinical settings for ulcerative colitis and IBS. Multiple RCTs show VSL#3 reduces IBS symptom scores, improves bloating, and in IBS-D specifically reduces stool frequency and improves consistency.
The high CFU count here is relevant because the strains in VSL#3 have been specifically validated at high doses — this is one case where CFU count genuinely matters to the clinical evidence.
Dose: One sachet (112.5 billion CFU) once or twice daily. The sachets must be refrigerated.
Products: VSL#3 sachets and capsules (available through their website and some pharmacies; the "medical food" version requires physician involvement; the consumer version is OTC)
Who it's best for: More severe IBS, IBS-D, IBS with significant bloating; people who haven't responded to single-strain probiotics.
Saccharomyces boulardii: specifically for IBS-D and post-antibiotic symptoms
S. boulardii is a yeast (not a bacterium) with a completely different mechanism of action than bacterial probiotics. It's not a commensal gut organism — it passes through transiently — but during its residence time it produces proteases that inactivate bacterial toxins, reduces intestinal permeability, and modulates the gut immune response.
Multiple RCTs support S. boulardii for:
- IBS-D: Reduces stool frequency and improves stool consistency
- Post-antibiotic diarrhea: The strongest single evidence base for this use
- Traveler's diarrhea: Prevention and treatment
Dose: 250–500 mg (approximately 5–10 billion CFU) twice daily, taken with meals. Can be taken during antibiotic courses — unlike bacterial probiotics, it's not killed by antibiotics.
Products: Florastor (most widely available, uses the CNCM I-745 strain, which has most of the clinical data), Jarrow Saccharomyces Boulardii.
Who it's best for: IBS-D predominantly; post-antibiotic gut disruption; concurrent antibiotic use.
What about the popular consumer brands?
Most widely-sold probiotic brands don't disclose their exact strain designations — they say "Lactobacillus acidophilus" without the strain identifier (e.g., LA-5, NCFM) that's essential for knowing if they match any clinical trial. A probiotic that says "10 billion CFU of Lactobacillus acidophilus" could contain any of dozens of strains with completely different effects.
This is not necessarily fraud — manufacturers have limited obligations to disclose strains — but it means you can't map the product to any specific clinical evidence.
Brands that do disclose strains meaningfully:
- Seed DS-01: Multi-strain, discloses specific strain identifiers, tested at the genome level
- Culturelle: Uses L. rhamnosus GG, which has strong diarrhea and gut health evidence (not specifically IBS, but one of the best-characterized strains in the world)
- Align: Discloses B. longum 35624 specifically
- Florastor: Discloses S. boulardii CNCM I-745 specifically
Why CFU count isn't everything
To be direct: 100 billion CFU of the wrong strain does nothing for IBS. 1 billion CFU of B. longum 35624 has RCT evidence for IBS improvement. The number means nothing without the strain context.
Additionally, most probiotic bacteria don't survive the gastric acid journey in the quantities advertised. Enteric-coated capsules and specific manufacturing methods (lyophilization) improve survival, but a lot of the listed CFU count at the time of labeling doesn't survive to the colon intact. This is another reason that focusing on well-studied strains at their clinical doses beats chasing high CFU numbers.
Practical approach: choose based on your IBS subtype
| IBS type | First-line strain choice | Alternative | |---|---|---| | IBS-D (diarrhea-predominant) | S. boulardii | VSL#3 | | IBS-C (constipation-predominant) | L. plantarum 299v | B. longum 35624 | | IBS-M (mixed) | B. longum 35624 (Align) | VSL#3 | | Bloating primary symptom | L. plantarum 299v | B. longum 35624 | | Post-antibiotic IBS flare | S. boulardii | L. rhamnosus GG | | Post-infectious IBS | VSL#3 | B. longum 35624 |
Give any single strain at least 4–8 weeks before evaluating. Some people see improvement at 2 weeks; the RCTs consistently run 4–12 weeks for meaningful data.
The bottom line
Probiotic efficacy in IBS is strain-specific, not brand-specific or CFU-count-specific. The four best-evidenced options are B. longum 35624 (Align) for general IBS with abdominal pain, L. plantarum 299v for bloating and gas, VSL#3 for more severe or diarrhea-predominant IBS, and S. boulardii specifically for IBS-D and post-antibiotic disruption. Buy products that disclose their exact strain designations, match the strain to your subtype, and give it a full clinical trial's worth of time — at least 4–8 weeks consistently.
Track your probiotic protocol alongside dietary changes and IBS symptoms to identify what's actually working for you. Use Optimize free.
Related Articles
Related Supplement Interactions
Learn how these supplements interact with each other
Omega-3 + Vitamin D3
Omega-3 fatty acids and Vitamin D3 are among the most commonly recommended supplements worldwide, an...
St. John's Wort + SAMe
St. John's Wort and SAMe (S-Adenosyl-L-Methionine) should not be combined due to the risk of seroton...
5-HTP + SAMe
5-HTP and SAMe should not be taken together because both supplements increase serotonin levels throu...
Omega-3 + CoQ10
Omega-3 fatty acids and CoQ10 (Coenzyme Q10) form a powerful cardiovascular support combination with...
Related Articles
More evidence-based reading
Akkermansia Muciniphila: The Gut Bacteria That Affects Metabolism and Weight
Akkermansia muciniphila is a keystone gut bacterium whose abundance strongly predicts metabolic health, gut barrier integrity, and response to weight loss interventions — and it can be deliberately cultivated.
8 min read →Resistant Starch for Gut Health: The Prebiotic That Changes Body Composition
Resistant starch is one of the few dietary compounds with simultaneous evidence for improving gut microbiome diversity, reducing postprandial glucose, and improving body composition — through mechanisms that are now well understood.
9 min read →Butyrate Supplements: What This Short-Chain Fatty Acid Does for Your Gut
Butyrate is the primary fuel source for colon cells and a critical regulator of gut barrier function, inflammation, and even gene expression — but supplementing it effectively is more complicated than it appears.
8 min read →